CLN3 disease

CLN3 disease, also known as juvenile neuronal ceroid lipofuscinosis (JNCL), juvenile Batten disease, or Spielmeyer-Vogt-Sjögren disease, is a rare inherited lysosomal storage disorder belonging to the neuronal ceroid lipofuscinoses (NCL) group. It is caused by mutations in the CLN3 gene on chromosome 16p12, which encodes a lysosomal/endosomal membrane protein. The disease is characterized by the accumulation of autofluorescent lipopigment (ceroid lipofuscin) in neurons and other cell types throughout the body, leading to progressive neurodegeneration. The hallmark presenting symptom is rapid progressive vision loss beginning between ages 4 and 8 years, typically leading to blindness within 2 to 4 years of onset. This is followed by progressive cognitive decline, behavioral changes, speech deterioration, and seizures that usually develop between ages 7 and 18. Motor function progressively deteriorates, with the development of extrapyramidal and pyramidal signs, leading to loss of independent ambulation. Cardiac involvement, particularly ECG abnormalities and cardiomyopathy, may also occur. The central nervous system is the most severely affected organ system, with progressive cerebral and cerebellar atrophy visible on neuroimaging. There is currently no cure for CLN3 disease. Treatment is supportive and symptomatic, focusing on seizure management with antiepileptic medications, physical and occupational therapy to maintain function, speech therapy, and psychological support for patients and families. Several experimental therapies including gene therapy, enzyme replacement, and small molecule approaches are under investigation. Life expectancy is significantly reduced, with most patients surviving into their twenties or thirties, though this varies. The disease follows a relentlessly progressive course, and multidisciplinary care is essential to optimize quality of life.

Common questions about CLN3 disease